1 Broad Institute of MIT and Harvard, Cambridge, MA, USA.
2 Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA.
3 Novartis Institute for Biomedical Research Inc, Cambridge, MA, USA.
4 Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
5 Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
6 Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
7 Novartis Institute for Biomedical Research Inc, Basel, Switzerland.
8 Department of Pediatrics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
9 Department of Immunology, K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
10 Broad Institute of MIT and Harvard, Cambridge, MA, USA. chuttenh@hsph.harvard.edu.
11 Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA. chuttenh@hsph.harvard.edu.
12 Broad Institute of MIT and Harvard, Cambridge, MA, USA. xavier@molbio.mgh.harvard.edu.
13 Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. xavier@molbio.mgh.harvard.edu.
14 Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA. xavier@molbio.mgh.harvard.edu.
In the Supplementary Tables 2, 4 and 6 originally published with this Article, the authors mistakenly included sample identifiers in the form of UMCGs rather than UMCG IBDs in the validation cohort; this has now been amended.